ISTH/X
Jun 11, 2025, 07:38
At ISTH 2025, Novo Nordisk Will Share Phase 3 Hemophilia Study Results
Novo Nordisk US shared on X:
“Novo Nordisk is presenting our latest hemophilia research data, including key phase 3 studies, at ISTH2025.”
Stay informed with Hemostasis Today.
-
May 30, 2026, 18:12Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
-
May 30, 2026, 18:11Alessandro Perrella: It is Not Only about “How High the CRP is”, but “in Which Patient” We are Measuring That Value
-
May 30, 2026, 18:11Jasper van Grunsven: Grateful for Our Rare Disease Team and the Commitment That Drives Our Mission
-
May 30, 2026, 18:10Open Registration for the 2026 Thrombosis Canada Annual Education Conference – Thrombosis Canada
-
May 30, 2026, 18:09Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
-
May 30, 2026, 17:07Deepak Yadav: A Privilege to Talk on ESUS at CREST Stroke Conclave 2026
-
May 30, 2026, 16:59Syed A Rizvi: Medical Scoring Systems – Small Numbers, Big Clinical Decisions
-
May 30, 2026, 16:53Timothy “Tim” Sheehan: BNY Wealth Joins the Fight Against Blood Disorders In Support of Hemophilia of Georgia
-
May 30, 2026, 16:51Nouf Bahri: Anticoagulation Initiation for New-Onset Atrial Fibrillation in Critical Illness